Health advocacy group sues AMA to make billing codes public
Rebecca Pifer Parduhn / healthcaredive - PatientRightsAdvocate.org is challenging the doctor’s association’s copyright of the current procedural terminology, or CPT, system. Use of the codes is required by law, and that means they should be freely available, per the suit.
AI Summary: A health advocacy group has taken the American Medical Association to court seeking public access to the CPT billing code system, arguing that proprietary control reduces transparency around medical billing and pricing. The legal action challenges AMA’s copyright and could force broader disclosure of codes used across U.S. healthcare.
Appeals Court Sides with Providers in No Surprises Act Pay Dispute
Katie Adams / medcitynews - A court ruling struck down key parts of how regulators calculate the No Surprises Act’s qualifying payment amount, siding with the Texas Medical Association’s argument that the formula has historically favored payers in arbitration. The post Appeals Court…
AI Summary: An appeals court has sided with providers, striking down the government’s method for calculating the No Surprises Act’s qualifying payment amounts and rejecting parts of the current QPA rule. The decision upends how out-of-network payment disputes are arbitrated, hands leverage back to providers, and injects fresh uncertainty into insurer-provider billing battles.
HCA Healthcare acquires 40 Texas urgent care centers
fiercehealthcare - The deal sees the facilities rebranded as CareNow sites, and many are being tied to the existing footprint of two affiliate systems.
AI Summary: Healthcare giant HCA has purchased 40 urgent care centers across Texas, folding dozens of local clinics into its national network. The move rapidly expands outpatient capacity and promises standardized operations and scale efficiencies — while predictably sparking questions about consolidation’s effects on pricing, local autonomy and patient experience.
FTC sues Hims & Hers over alleged privacy violations, deceptive billing practices
Jill Hughes / healthcaredive - Regulators say the telehealth company illegally shared patient health data with advertisers and misled its customers. Hims & Hers hit back, calling the claims “baseless.”
AI Summary: Federal regulators have filed a lawsuit accusing telehealth and wellness firm Hims & Hers of improperly handling consumer data and engaging in misleading billing practices. The action alleges privacy violations and deceptive charges tied to subscription services, prompting scrutiny of digital health companies that promised convenience — and apparently delivered confusion instead.
Coalition Urges Policymakers to Reject No Surprises Act Enforcement Bill
Marissa Plescia / medcitynews - The Coalition Against Surprise Medical Billing launched a campaign opposing the No Surprises Act Enforcement Act, arguing it would worsen IDR process abuse.The post Coalition Urges Policymakers to Reject No Surprises Act Enforcement Bill appeared first on…
AI Summary: A coalition of payers and allied groups has launched an organized push against proposed enforcement legislation tied to the No Surprises Act, including ad campaigns and formal warnings that current arbitration mechanisms need reform. Stakeholders argue the draft changes could distort payment resolution and are pressing lawmakers for modifications rather than straight enforcement.
- Insurers slam IDR; arbitration payouts soar (3)
- Payers' ad campaigns and coalition lobbying (3)
- Rising disputes as employers and lawmakers push reforms (3)
Insurers slam IDR; arbitration payouts soar
Payers' ad campaigns and coalition lobbying
Rising disputes as employers and lawmakers push reforms
CVS Caremark, FTC settle insulin pricing case for $13B
Ella Jeffries / beckershospitalreview - The Federal Trade Commission reached a settlement with CVS Caremark that requires the pharmacy benefit manager to change its business practices as part of the agency’s antitrust case alleging the PBM inflated insulin list prices through rebate practices. …
AI Summary: CVS Caremark agreed to a $13 billion settlement with the Federal Trade Commission to resolve allegations tied to its handling of insulin pricing and related business practices. The deal includes a large cash payment and operational changes designed to address the FTC’s concerns, and now awaits court approval and implementation details.
Thousands of Medicare Beneficiaries Thought Their Drug Plan Was Free. Then They Lost It.
Susan Jaffe / kffhealthnews - Thousands of people who had a Medicare drug plan with zero-dollar premiums last year got small premium increases this year — and didn’t know it. They were dropped from their coverage for failing to pay amounts as little as $8, and most can’t get it again …
AI Summary: Investigations reveal that many Medicare beneficiaries who believed their drug coverage was free later discovered they had lost benefits, often because of plan changes or confusing enrollment processes. The situation exposed gaps in consumer communication and program oversight, prompting calls for clearer disclosures and stronger safeguards to prevent future coverage surprises.
As PBM industry shifts, LucyRx and Abarca Health merge to build scale
fiercehealthcare - Amid significant shifts in the pharmacy benefit management industry, LucyRx and Abarca Health have revealed plans to merge to build the scale necessary to compete in this changing landscape.
AI Summary: Two independent pharmacy benefit managers, LucyRx and Abarca Health, announced a combination to build scale amid industry consolidation. The deal aims to bolster negotiating leverage, broaden client reach and offer an alternative to dominant PBMs—because apparently one disruptor wasn’t enough to disrupt the disruptors.
Indiana takes on powerful hospitals by capping prices they charge employers
medicalxpress - Tired of watching its employers struggle to afford the cost of health care, Republican-controlled Indiana is trying a traditionally liberal tactic to control costs: setting government price controls on hospitals.
AI Summary: Indiana enacted legislation capping the prices hospitals can charge employers, a bold move aimed at reining in dominant health systems that have long driven up commercial costs. The measure forces hospitals to accept lower, more predictable rates for employer-covered care, prompting industry pushback as the state tries to rebalance bargaining power.
Congressional Budget Office calls for more research on No Surprises Act unintended impacts
fiercehealthcare - The nonpartisan office is seeking more information on the law’s impact on healthcare prices, network participation, ownership structures and more.
AI Summary: The Congressional Budget Office has called for additional research into the No Surprises Act, urging deeper study of the law’s unintended consequences on pricing, provider networks and patient costs. Federal agencies and stakeholders are being pressed to produce better evidence so policymakers can evaluate whether the law’s goals align with real-world effects.
UnitedHealth, FTC reach proposed settlement in insulin case
Emily Olsen / healthcaredive - The tentative deal comes months after CVS Health reached a proposed settlement in the lawsuit alleging major pharmacy benefit managers are inflating insulin costs.
AI Summary: UnitedHealth/Optum Rx reached a proposed settlement with the FTC over alleged anti-competitive insulin rebate and pricing practices, including terms to resolve claims that rebates harmed competition and patients. The agreement would curb disputed pharmacy benefit manager conduct and could reshape how insulin discounts are negotiated and passed through to consumers.
CMS Finalizes Rule to Simplify Payer-Provider Disputes Under No Surprises Act
Katie Adams / medcitynews - CMS finalized a new rule aimed at streamlining the No Surprises Act’s overwhelmed arbitration system. Provider groups largely welcomed the reforms — though some industry leaders said additional changes are still needed to address alleged misuse and improv…
AI Summary: The Centers for Medicare & Medicaid Services finalized a rule to simplify payer‑provider disputes under the No Surprises Act, updating the dispute resolution process and implementing a payer registry and portal changes. The aim is to reduce administrative friction, speed dispute handling, and make billing arbitration less of an endurance sport for providers and insurers.
- Final rule: new portal and payer registry details (3)
- Insurers push back; provider legal fights over payments (3)
- Patient fallout: medical debt and surprise billing stories (3)
Final rule: new portal and payer registry details
Insurers push back; provider legal fights over payments
Patient fallout: medical debt and surprise billing stories
Optum Rx unveils new transparent PBM model
fiercehealthcare - UnitedHealth Group's pharmacy benefit manager, Optum Rx, is making the shift to a more transparent model, the company announced Monday.
AI Summary: Optum Rx unveiled a new pharmacy benefit model that separates drug list prices from PBM fees and adopts clearer pass‑through pricing. Aimed at employers and payers fed up with opaque pharmacy economics, the proposal promises simpler contracts and fee clarity — an attempt to make PBMs boringly accountable and maybe slightly less profitable.
- Industry responses to rising drug costs and PBM models (4)
- Lawmakers and states press PBM vertical-integration reform (4)
- Optum Rx unveils transparent PBM model (4)
- All Other Stories
Industry responses to rising drug costs and PBM models
Lawmakers and states press PBM vertical-integration reform
Optum Rx unveils transparent PBM model
All Other Stories
340B drug discounts are drifting from patients to profit, and reform is now on the table
medicalxpress - The 340B Drug Pricing Program must be reformed to better patient health and disincentivize institutional profit-seeking behaviors, says the American College of Physicians (ACP). In a new policy, "Reforming 340B to Promote Program Integrity and Better Serv…
AI Summary: The 340B drug-discount program is under renewed scrutiny after analyses and advocacy groups argue discounts intended to help patients are instead boosting institutional margins. Hospitals, provider groups and the AHA are contesting HRSA proposals and court rulings, sparking policy debates and potential regulatory fixes to curb markups and steer savings back to vulnerable patients.
FDA approves Travere's Filspari as first drug for the kidney disease called FSGS
Nicole DeFeudis / endpoints - The FDA expanded the label for Filspari on Monday to add another kidney condition. The drug is now the first therapy approved in the US for focal segmental glomerulosclerosis (FSGS). The pill may be taken ...
AI Summary: The FDA approved Filspari for focal segmental glomerulosclerosis (FSGS), delivering the first specifically authorized treatment for this rare kidney disease. The approval provides a targeted therapeutic option for patients and marks a commercial milestone for Travere, raising hopes for better outcomes while spotlighting questions about access, pricing, and long‑term real‑world effectiveness.
New Bill Seeks to Lower Out-of-Pocket Drug Costs
Marissa Plescia / medcitynews - Rep. Greg Murphy introduced a bill that would require out-of-pocket prescription drug spending to count toward patients’ deductibles and out-of-pocket maximums regardless of where the drugs are purchased.The post New Bill Seeks to Lower Out-of-Pocket Drug…
AI Summary: Lawmakers introduced legislation to reduce out‑of‑pocket drug costs by allowing patients' direct drug purchases to count toward their insurance deductibles. The proposal aims to ease financial strain for people buying costly medications out‑of‑pocket, but would require insurers and pharmacy systems to change longstanding accounting and benefits practices.
High-dose Wegovy debuts at $399 for self-paying patients
Paige Twenter / beckershospitalreview - Novo Nordisk’s recently approved high-dose Wegovy formulation has entered the U.S. market and is available for $399 per month for self-paying patients, the drugmaker said April 7. In March, the FDA approved Wegovy HD, a 7.2-mg injection of semaglutide, as…
AI Summary: Novo Nordisk has introduced a higher‑dose formulation of Wegovy (semaglutide) in the U.S., offering self‑pay patients access at a $399 monthly price. The rollout reflects growing demand for GLP‑1 therapies and fuels ongoing debates about affordability, access and how much of weight‑management care should depend on out‑of‑pocket spending.
- On scene: industry shifts, IPOs, stigma and miscellaneous reports (4)
- On site: Novo rolls out Wegovy HD, sparking access debates (7)
- Regulators press for more GLP-1 safety data and oversight (4)
- Reporting from clinics: GLP-1s vary in effect, risk muscle loss (9)
- All Other Stories
On scene: industry shifts, IPOs, stigma and miscellaneous reports
On site: Novo rolls out Wegovy HD, sparking access debates
Regulators press for more GLP-1 safety data and oversight
Reporting from clinics: GLP-1s vary in effect, risk muscle loss
All Other Stories
Patients Are Using Chatbots to Fight Medical Bills, With Mixed Results
Sarah Kwon / nytimes - While chatbots like Claude and ChatGPT can help narrow the information divide between patients and providers, they can also dispense flawed advice.
AI Summary: Patients increasingly use AI chatbots to challenge medical bills, leveraging automated appeals and negotiation scripts. While chatbots can speed administrative tasks and sometimes reduce balances, outcomes vary and users face inconsistent accuracy and limits in handling complex payer disputes—so yes, convenience at the price of occasional frustration.
AbbVie sues HHS over 340B patient definition
Ella Jeffries / beckershospitalreview - AbbVie has filed a lawsuit challenging federal guidance on how “patient” is defined under the 340B program, according to an April 8 press release. The company said the current definition, based on guidance issued in 1996, allows covered entities to claim …
AI Summary: AbbVie has filed suit challenging HHS’s interpretation of the 340B program, arguing the agency’s “patient” definition and related guidance are outdated and legally flawed. The company seeks judicial clarity that could reshape who qualifies for discounted drugs and how hospitals and manufacturers navigate the program — yes, the pricing drama continues.
Memorial Hermann goes out of network with BCBS Texas
Elizabeth Casolo / beckershospitalreview - Houston-based Memorial Hermann Health System’s contract with BCBS Texas expired April 1, rendering the health system out of network. Commercial and ACA exchange (both individual and family) plan members lost access at the end of March. Memorial Hermann ha…
AI Summary: Memorial Hermann and Blue Cross Blue Shield of Texas failed to agree on a new contract, resulting in the health system going out of network for affected plan members. Patients face potential higher costs and care disruptions while negotiators jockey publicly; both sides warn of financial stakes and urge members to stay informed.